standard adjuvant chemotherapy plus moxifloxacin — Competitive Intelligence Brief

standard adjuvant chemotherapy plus moxifloxacin (standard adjuvant chemotherapy plus moxifloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fluoroquinolone antibiotic. Area: Infectious Diseases.

phase 3 fluoroquinolone antibiotic DNA gyrase and topoisomerase IV Infectious Diseases Small molecule

Target snapshot

standard adjuvant chemotherapy plus moxifloxacin (standard adjuvant chemotherapy plus moxifloxacin) — Sun Yat-sen University. Moxifloxacin is a broad-spectrum antibiotic that inhibits bacterial DNA replication by binding to the bacterial DNA gyrase and topoisomerase IV.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
standard adjuvant chemotherapy plus moxifloxacin TARGET	standard adjuvant chemotherapy plus moxifloxacin	Sun Yat-sen University	phase 3	fluoroquinolone antibiotic	DNA gyrase and topoisomerase IV
Moxifloxacin (Topical)	Moxifloxacin (Topical)	University of California, San Francisco	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Experimental: Active "I-Reconstruction" Therapy	Experimental: Active "I-Reconstruction" Therapy	International Association Psychosomatics And Health Therapy	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
β-lactams or ciprofloxacin	β-lactams or ciprofloxacin	University of Athens	marketed	Antibiotic (β-lactam and fluoroquinolone)	Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin)
Gatifloxacin 0.3%	Gatifloxacin 0.3%	Innovative Medical	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
moxifloxacin 0.5% HCI ophthalmic solution	moxifloxacin 0.5% HCI ophthalmic solution	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Vigamox Eye Drops	Vigamox Eye Drops	Merck Sharp & Dohme LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fluoroquinolone antibiotic class)

1. Allergan · 1 drug in this class
2. Shenzhen Third People's Hospital · 1 drug in this class
3. Sun Yat-sen University · 1 drug in this class
4. University of Rochester · 1 drug in this class